{"Clinical Trial ID": "NCT00915018", "Intervention": ["INTERVENTION 1:", "Neratinib + Paclitaxel", "Neratinib + Paclitaxel", "Neratinib: Neratinib - 240 mg orally administered once daily. Treatment will be given until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8 and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "INTERVENTION 2:", "Trastuzumab + Paclitaxel", "Trastuzumab + Paclitaxel", "Trastuzumab: Trastuzumab - initial loading dose of 4 mg/kg IV followed by a subsequent weekly dose of 2 mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8 and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent."], "Eligibility": ["Incorporation criteria:", "ErbB-2 positive locally recurrent or metastatic breast cancer", "Eastern Cooperative Oncology Group (ECOG) 0-2", "A Measurable Disease", "Availability of tumour tissue for confirmation of HER2 status", "- Exclusion criteria:", "- Previous systemic cancer treatment other than endocrine treatment for locally recurrent or metastatic diseases", "Inhibitor of erbB-2 other than trastuzumab or lapatinib in the neoadjuvant or adjuvant setting", "Progression/repetition within 12 months of completion of adjuvant or neoadjuvant treatment", "\u2022 History of heart disease", "gastrointestinal disease history"], "Results": ["Performance measures:", "- Survivors without progression", "Defined as the interval between the date of randomization and the first date on which recurrence or progression, or death due to any cause, is documented, censored at the time of the last evaluable evaluation or at the beginning of a new anticancer treatment.", "Timeline: From randomization to disease progression or death, estimated to be up to 5.3 years", "Results 1:", "Title of arm/group: Neratinib + Paclitaxel", "Description of the arm/group: Neratinib + Paclitaxel", "Neratinib: Neratinib - 240 mg orally administered once daily. Treatment will be given until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8 and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "Total number of participants analysed: 242", "Median (95% confidence interval)", "Unit of measure: month 12.9 (11.1-14.9)", "Results 2:", "Title of arm/group: Trastuzumab + Paclitaxel", "Description of the arm/group: Trastuzumab + Paclitaxel", "Trastuzumab: Trastuzumab - initial loading dose of 4 mg/kg IV followed by a subsequent weekly dose of 2 mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "Paclitaxel: Paclitaxel - 80 mg/m2 IV administered on days 1, 8 and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.", "Total number of participants analysed: 237", "Median (95% confidence interval)", "Unit of measure: month 12.9 (11.1 to 14.8)"], "Adverse Events": ["Undesirable Events 1:", "Total: 67/240 (27.92%)", "Anemia 0/240 (0.00 %)", "Febrile neutropenia 1/240 (0.42%)", "- Leucopenia 2/240 (0.83%)", "Neutropenia 1/240 (0.42%)", "Thrombocytopenia 0/240 (0.00 %)", "Atrial fibrillation 0/240 (0.00 %)", "Congestive heart failure 2/240 (0.83%)", "Cardiac tamponade 1/240 (0.42%)", "Cardiorespiratory arrest 1/240 (0.42%)", "- Left ventricular dysfunction 0/240 (0.00 %)", "Adverse Events 2:", "Total: 56/234 (23.93 per cent)", "Anemia 1/234 (0.43%)", "- Febrile neutropenia 0/234 (0.00 %)", "Leukopenia 0/234 (0.00 %)", "Neutropenia 0/234 (0.00 %)", "Thrombocytopenia 1/234 (0.43%)", "Atrial fibrillation 1/234 (0.43%)", "Congestive heart failure 0/234 (0.00 %)", "- Cardiac Tapponade 0/234 (0.00 %)", "Cardiorespiratory arrest 0/234 (0.00 %)", "Left ventricular dysfunction 1/234 (0.43%)"]}